USPTO serial 79378524
Serial No. 79378524
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Dec 24, 2024
- Examiner
- EISNACH, MICHAEL PATRICK
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with Serial No. 79378524?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Polypeptide Laboratories Holding (PPL) AB
SE
Other trademarks owned by Polypeptide Laboratories Holding (PPL) AB
Polypeptide Laboratories Holding (PPL) AB
SE
Other trademarks owned by Polypeptide Laboratories Holding (PPL) AB
Polypeptide Laboratories Holding (PPL) AB
SE
Other trademarks owned by Polypeptide Laboratories Holding (PPL) AB
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Bethany J. Whelan
Bethany J. Whelan Dority & Manning, P.A.P.O. Box 1449PO BOX 2086Greenville, SC 29602-1449Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biological preparations for use in industry and science; peptides for industrial purposes; oligonucleotides for industrial purposes | ACTIVE | — |
| 003 | Non-medicated soaps; perfumery; essential oils; cosmetics; hair lotions; dentifrices | ACTIVE | — |
| 005 | Synthetic peptides for pharmaceutical purposes, namely, for use in oncology, metabolic disorders, neurology, gastrointestinal diseases, cardiovascular, reproductive health, immune system, nutritional disorders hormonal disorders, musculoskeletal disorders, anesthetics, cns, immunology for the treatment of obesity, diabetes, cancer, endometriosis, up-regulation of growth hormone, lipodystrophy in hiv/aids, sleeping disorders, endometriosis, autoimmune diseases, esophageal hemorrhage, hypercalcemia, dental infiltration, irritable bowel syndrome, hypotension, achondroplasia, multiple myeloma, non-metastatic osteosarcoma, erectile dysfunction, delaying imminent pre-term birth, postpartum hemorrhage, spinocerebellar degeneration, hypoactive sexual desire disorder, osteoporosis, post-menopausal osteoporosis, chronic idiopathic constipation, acute decompensated heart failure, sepsis and septic shock, acute attacks of hereditary angioedema, gastrointestinal bleeding, treatment of hiv-1, reduction of hiv lipodystrophy, severe chronic pain, chronic immune thrombocytopenic purpura, treatment of anemia associated with kidney disease, prevention of respiratory distress syndrome, prevention of phototoxicity, myocardial infarction, treatment of refractory hypotension in adults with septic or other distributive shock, irritable bowel syndrome, myasthenia gravis, uremic pruritus, renal puritus, hepatorenal syndrome, growth hormone related diseases, acromegaly, esophageal varices, bed wetting, polyuria, hyperuresis, hemophilia a, premature labor, tocolysis, autoimmune diseases, infantile spasms, rheumatoid arthritis, multiple sclerocsis, hepatitis b, treatment of chushing's disease, treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, diagnose of somatostatin receptor-positive neuroendocrine tumors, bacterial infections, viral infections, fungal infections, cardiovascular diseases, endocrine disorders, neurological conditions, allergic reactions plant; synthetic oligonucleotides for pharmaceutical purposes for use in oncology, neurology, rare diseases for the treatment of genetic disorders, neurodegenerative diseases and cancer; pharmaceutical and veterinary preparations, namely, synthetic peptides for pharmaceutical and veterinary purposes for fertility control in animals, induction of ovulation in mares, castration of dogs, facilitation of parturition in livestock; biological preparations for medical and veterinary purposes, namely, polypetide biochemicals for medical and veterinary purposes for oncology, metabolic disorders, neurology, gastrointestinal diseases, cardiovascular, reproductive health, immune system, nutritional disorders hormonal disorders, musculoskeletal disorders, anesthetics, cns, immunology for the treatment of obesity, diabetes, cancer, endometriosis, up-regulation of growth hormone, lipodystrophy in hiv/aids, sleeping disorders, endometriosis, autoimmune diseases, esophageal hemorrhage, hypercalcemia, dental infiltration, irritable bowel syndrome, hypotension, achondroplasia, multiple myeloma, non-metastatic osteosarcoma, erectile dysfunction, delaying imminent pre-term birth, postpartum hemorrhage, spinocerebellar degeneration, hypoactive sexual desire disorder, osteoporosis, post-menopausal osteoporosis, chronic idiopathic constipation, acute decompensated heart failure, sepsis and septic shock, acute attacks of hereditary angioedema, gastrointestinal bleeding, treatment of hiv-1, reduction of hiv lipodystrophy, severe chronic pain, chronic immune thrombocytopenic purpura, treatment of anemia associated with kidney disease, prevention of respiratory distress syndrome, prevention of phototoxicity, myocardial infarction, treatment of refractory hypotension in adults with septic or other distributive shock, irritable bowel syndrome, myasthenia gravis, uremic pruritus, renal puritus, hepatorenal syndrome, growth hormone related diseases, acromegaly, esophageal varices, bed wetting, polyuria, hyperuresis, hemophilia a, premature labor, tocolysis, autoimmune diseases, infantile spasms, rheumatoid arthritis, multiple sclerocsis, hepatitis b, treatment of chushing's disease, treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, diagnose of somatostatin receptor-positive neuroendocrine tumors, bacterial infections, viral infections, fungal infections, cardiovascular diseases, endocrine disorders, neurological conditions, allergic reactions plant; medicated dandruff and hair loss shampoos, medicated hair lotions for treating dandruff hair loss and hair damage, medicated soap cleansers for the skin, and medicated cosmetics, namely creams for treating acne, irritated, itching, and inflamed skin, repairing skin damage and promoting wound healing; medical being medicated hair lotion; medicated soap; sanitary preparations for medical purposes; medicated and sanitizing soaps and detergents; dietetic substances in the nature of protein dietary supplements; protein nutritional supplements; collagen dietary supplements; collagen nutritional supplements; collagen peptide dietary supplements; collagen peptide nutritional supplements adapted for medical use; food for babies; dietetic food adapted for medical use; dietetic food adapted for veterinary use; plasters for medical purposes; materials for dressings, namely, medical dressings; material for stopping teeth; dental wax; disinfectants; preparations for destroying vermin; fungicides; herbicides; vaccines | ACTIVE | — |
| 035 | Advertising services; business administration; business management; providing office function | ACTIVE | — |
| 040 | Custom manufacturing services for others in the field of peptide and olignuclotide manufacturing | ACTIVE | — |
| 042 | Research and development services relating to vaccines; product research and development services; research and development services in the field of peptide and oligonucleotide manufacturing | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Polypeptide Laboratories Holding (PPL) AB
- Other trademarks owned by Polypeptide Laboratories Holding (PPL) AB
- Other trademarks owned by Polypeptide Laboratories Holding (PPL) AB
- Other trademarks in Class 001
- Other trademarks in Class 003
- Other trademarks in Class 005
- Other trademarks in Class 035
- Other trademarks in Class 040
- Other trademarks in Class 042
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 28, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Dec 24, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Dec 24, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 22, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 22, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 2, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 16, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 16, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Sep 16, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Sep 16, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Sep 16, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Aug 28, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 28, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 28, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 19, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Feb 28, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Feb 28, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Feb 7, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Feb 6, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 31, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 19, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 15, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 14, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |